亨廷顿病:了解它的新药和治疗方法
Hitaansh Dhingra1, Shilpa A Gaidhane1
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|November 29, 2023
概括
亨廷顿病 (HD) 的治疗重点是控制症状,探索基因疗法,如RNA干扰和CRISPR-Cas9,以阻止疾病的进展. 进一步的研究对于治愈至关重要.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 亨廷顿病 (HD) 是一种遗传性神经退行性疾病,其特点是运动,认知和精神症状.
- 由HTT基因突变引起,导致异常的猎蛋白积累,主要影响条纹体和大脑皮层.
- 疾病严重影响患者和家人的生活质量,通常在成年期中期表现出来.
研究的目的:
- 为亨廷顿病提供当前和新兴治疗方法的概述.
- 讨论症状管理和疾病修饰的策略.
- 突出基因疗法在治疗HD方面的潜力.
主要方法:
- 对运动和精神症状的药物干预措施的审查 (例如,四贝纳,二贝纳,抗抑郁药,抗精神病药).
- 探索包括RNA干扰 (RNAi) 在内的疾病修饰策略,以减少突变的亨廷丁蛋白合成.
- 研究基因编辑技术,如CRISPR-Cas9,用于潜在的突变逆转.
主要成果:
- 目前的药物治疗旨在缓解诸如非自愿运动和精神障碍等症状.
- 非药物疗法,包括身体,语言和职业治疗,提高功能能力和幸福感.
- 基因疗法,如RNAi和CRISPR-Cas9,有望阻止疾病的进展,并可能扭转遗传原因.
结论:
- 在亨廷顿病治疗方面取得了重大进展,重点是症状控制和疾病修饰.
- 基因治疗为未来的疾病干预提供了有希望的途径.
- 为了开发更有效的治疗方法,并最终找到对HD的治疗方法,继续进行研究是必不可少的.
相关概念视频
01:26Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:15Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557